Hip Embolization

Chronic hip pain has several overlapping causes. Hip osteoarthritis (OA) is degeneration of the cartilage lining the femoral head and acetabulum, causing bone-on-bone friction, stiffness, and deep groin or lateral hip pain. Greater trochanteric pain syndrome (GTPS) — commonly called hip bursitis — involves inflammation of the trochanteric bursa, a fluid-filled sac overlying the bony prominence on the outer hip, and of the surrounding gluteal tendons. Both conditions share a critical mechanism: abnormal proliferation of small blood vessels (neovascularization) within the inflamed tissue, which carries pain-signaling nerve fibers and pro-inflammatory mediators that perpetuate the pain cycle. Hip OA affects over 10% of adults over 60, and GTPS is estimated to affect up to 25% of people with chronic hip pain, particularly women.

Hip embolization is a catheter-based, image-guided procedure that selectively blocks the abnormal inflammatory blood vessels supplying the hip joint capsule, synovial lining, and periarticular soft tissues (including the bursa and gluteal tendon insertions). By cutting off this neovascular supply, the procedure interrupts the inflammatory cascade at its source — an effect that injections cannot replicate. Corticosteroid injections suppress inflammation temporarily but do not eliminate the pathological vessels; as a result, relief typically lasts only 6–12 weeks before the inflammatory supply re-establishes itself. Hip embolization creates a more durable change in the tissue environment, with clinical results lasting well beyond 12 months in published series. Importantly, it does not involve any instrumentation of the hip joint itself and does not affect the cartilage or bone.

Ideal candidates are patients with chronic hip pain — from osteoarthritis, greater trochanteric pain syndrome (bursitis), or synovitis — who have had inadequate or short-lived relief from conservative treatments including physical therapy, NSAIDs, corticosteroid injections, or PRP. Patients who are not surgical candidates due to age, comorbidities, or anticoagulation are excellent candidates. Hip embolization is also appropriate for patients who are not yet ready for total hip replacement (THR) and want a non-surgical option to bridge or avoid surgery altogether. A recent MRI or X-ray of the hip, along with a clinical history, is reviewed at consultation to confirm candidacy.

The procedure is performed in our office-based lab under mild conscious sedation and local anesthesia. A microcatheter is advanced from the radial artery at the wrist through the aorta and into the branches of the femoral and internal iliac artery systems supplying the hip. Digital subtraction angiography (DSA) or cone-beam CT identifies the hyperemic blush of inflamed periarticular tissue — the target zone. Tiny embolic microspheres (100–300 microns) are carefully injected to selectively reduce blood flow to the pathological neovessels while preserving normal arterial supply to muscle and bone. For bursitis-predominant cases, the lateral circumflex femoral artery branches and trochanteric vessels are also addressed. The procedure takes approximately 60–90 minutes, and most patients go home the same afternoon.

Most patients begin noticing reduced hip pain and improved mobility within 2–4 weeks of the procedure. The inflammatory response continues to resolve as the treated neovessels regress, with most patients reaching their maximum benefit at 4–8 weeks. In published case series and early clinical trial data, approximately 70–80% of patients report meaningful pain reduction at 6–12 months. Physical therapy begun 3–4 weeks after embolization — when pain levels have dropped sufficiently — can further accelerate functional recovery, particularly for patients with gluteal tendon involvement.

The embolic microspheres used for hip embolization are sized to target only the small-caliber pathological neovessels within the inflamed periarticular tissue, not the larger arteries supplying the femoral head with its primary blood supply (the medial and lateral femoral circumflex arteries). The most feared complication of hip vascular injury — avascular necrosis (AVN) of the femoral head — has not been reported in published hip embolization series when procedures are performed with appropriate particle size selection and careful angiographic technique. Post-procedure MRI follow-up in published cohorts has shown no evidence of AVN, cartilage damage, or gluteal muscle ischemia.

Recovery from hip embolization is notably straightforward. Most patients return home the same day with a small bandage at the wrist. Mild post-procedural hip aching, warmth, or pelvic discomfort for 2–5 days is common and represents the post-embolization syndrome — manageable with ibuprofen and rest. There are no restrictions on weight-bearing immediately after the procedure; patients can walk normally the next day. Strenuous activity and impact exercise are recommended to be avoided for 1–2 weeks. A follow-up visit at 4–6 weeks allows reassessment and, if indicated, referral to physical therapy for rehabilitation.

Yes. Hip embolization is not an all-or-nothing intervention and works well as part of a comprehensive pain management strategy. Physical therapy initiated 3–4 weeks post-procedure — once the acute inflammatory reduction has taken hold — is strongly encouraged for patients with bursitis or tendinopathy to rebuild hip abductor strength and correct biomechanical loading. A short course of NSAIDs in the post-procedural period assists with comfort. For patients with hip OA, embolization can provide a meaningful window of pain relief during which they improve conditioning, lose weight, or defer surgery until the optimal time. It does not preclude future corticosteroid injections or total hip replacement.

Total hip replacement (THR) is the definitive treatment for end-stage hip OA and remains the gold standard when significant joint destruction is present. However, it involves major surgery, general or spinal anesthesia, a 1–3 night hospital stay, and a 6–12 week functional recovery. Implant complications — dislocation, infection, wear, loosening — and the finite 15–20 year lifespan of prosthetic components are additional considerations, particularly for younger patients. Hip embolization is not a substitute for THR in advanced OA, but it is a meaningful option for patients with moderate disease (Kellgren-Lawrence grade 1–3) or bursitis-predominant pain who wish to delay, defer, or avoid surgery — or for those who are medically ineligible for general anesthesia.

Hip embolization for chronic pain is an emerging procedure and insurance coverage is currently variable, similar to genicular artery embolization in its earlier adoption phase. Some commercial plans and Medicare Advantage carriers will consider coverage when a well-documented history of failed conservative therapy is provided, along with imaging confirming the diagnosis and clinical notes substantiating medical necessity. Our team prepares comprehensive prior authorization documentation and will advise you on expected coverage before scheduling. Self-pay options are also available, and costs compare favorably to the cumulative expense of repeated injection cycles over time.